Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG20 With Carboplatin and Cabazitaxel in Aggressive Variant Prostate Cancers
NCT06085729Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pegargiminase in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Started Feb 2024; status: recruiting.
02
Drugs
Pegargiminase
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06085729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085729.